ArticleJournal of robotic surgery2026
Early experience with robot-assisted radical prostatectomy using the Toumai system: outcomes from the first African series of 134 patients.
Article in Journal of robotic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Robot-assisted radical prostatectomy (RARP) is widely used for localized prostate cancer, offering enhanced precision and potential preservation of urinary and sexual function. Data on new robotic platforms in Africa are limited. Evaluate the safety, feasibility, and early perioperative, oncological, and functional outcomes of robot-assisted radical prostatectomy performed using the Toumai robotic system and determine whether these outcomes are consistent with those reported for established robotic platforms. We retrospectively analyzed 134 patients who underwent RARP with the Toumai system between May 2024 and November 2025. Preoperative data, perioperative parameters, pathological findings, functional outcomes, and postoperative PSA were collected. Urinary continence and erectile function were assessed at 1, 3, 6, 9, and 12 months postoperatively. The mean age was 67.3 years and mean preoperative PSA was 13.47 ng/mL. Most patients were intermediate risk (52.2%). Mean operative time was 262.8 min, with low blood loss (65.9 mL) and one conversion to open surgery (0.75%). Mean hospital stay was 1.4 days. Postoperative complications were rare (14.9% Clavien-Dindo I-II, 1.5% major), with no mortality. Positive surgical margins occurred in 11.1%, and lymph node involvement in 8%. After a median follow-up of 6 months (IQR: 3-18 months), 19.5% of patients showed biochemical recurrence. Urinary continence improved progressively from 30.6% at 1 month to 60.9% at 9 months and 88.2% at 12 months. Spontaneous erectile function increased from 17.6% at 3 months to 41.2% at 12 months. RARP with the Toumai system is safe and feasible in an African setting, showing acceptable early oncological outcomes with short follow-upand progressive functional recovery. Early biochemical control and continence rates are encouraging, while erectile function recovery remains gradual, highlighting the impact of surgical experience and the need for structured rehabilitation and long-term follow-up.
Indexed as
Identifiers
42474873What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.